DifGen Pharmaceuticals LLC has acquired KriGen LLC a fully integrated sterile drug product manufacturer with capability to manufacture a wide range of parenteral products including LVP bags (both aseptic and terminally sterilized), PFS, microspheres and complex long acting injectables.
 
In a joint statement, Ramandeep Singh Jaj & Dr. Santhanakrishnan Srinivasan, Founders and Co-CEO’s of DifGen commented, “The acquisition of KriGen LLC is expected to complement DifGen’s strong scientific capability of developing complex injectable products. This strategic investment allows us the capability to manufacture complex and high-barrier to entry sterile products in-house. This helps secure supply to our valuable partners with local US based manufacturing. Most importantly, it will provide patients, affordable lifesaving medication with highest quality, consistent supply & ensure the burden of drug shortages are minimized.”
 
DifGen is a U.S. based global pharmaceutical company with a primary focus on developing complex high barrier to entry generics and specialty pharmaceutical products.
 
KriGen is a pharmaceutical company with a state-of-the-art parenteral manufacturing facility in Lillington, NC. At its full operational capacity KriGen is capable of manufacturing close to 25-30 million units of LVP bags, pre-filled syringes and strategic long-acting depot injections.